On Monday, Plus Therapeutics Inc (NASDAQ: PSTV) opened lower -18.09% from the last session, before settling in for the closing price of $1.16. Price fluctuations for PSTV have ranged from $0.24 to $2.67 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 383.24%. Company’s average yearly earnings per share was noted 83.76% at the time writing. With a float of $11.48 million, this company’s outstanding shares have now reached $11.79 million.
In terms of profitability, gross margin is 26.42%, operating margin of -343.29%, and the pretax margin is -301.83%.
Plus Therapeutics Inc (PSTV) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Plus Therapeutics Inc is 2.55%, while institutional ownership is 16.02%. The most recent insider transaction that took place on Sep 13 ’24, was worth 5,996. In this transaction Director of this company bought 4,000 shares at a rate of $1.50, taking the stock ownership to the 15,188 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Director bought 6,285 for $1.35, making the entire transaction worth $8,512. This insider now owns 11,188 shares in total.
Plus Therapeutics Inc (PSTV) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 83.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 48.21% during the next five years compared to 48.41% growth over the previous five years of trading.
Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators
Check out the current performance indicators for Plus Therapeutics Inc (PSTV). In the past quarter, the stock posted a quick ratio of 0.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.89, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of Plus Therapeutics Inc (PSTV)
Compared to the last year’s volume of 16.25 million, its volume of 10.18 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 45.26%. Additionally, its Average True Range was 0.35.
During the past 100 days, Plus Therapeutics Inc’s (PSTV) raw stochastic average was set at 34.31%, which indicates a significant increase from 28.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 513.22% in the past 14 days, which was higher than the 334.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1027, while its 200-day Moving Average is $1.3583. Nevertheless, the first resistance level for the watch stands at $1.0884 in the near term. At $1.2267, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3034. If the price goes on to break the first support level at $0.8734, it is likely to go to the next support level at $0.7967. Should the price break the second support level, the third support level stands at $0.6584.
Plus Therapeutics Inc (NASDAQ: PSTV) Key Stats
There are currently 5,896K shares outstanding in the company with a market cap of 11.20 million. Presently, the company’s annual sales total 4,910 K according to its annual income of -13,320 K. Last quarter, the company’s sales amounted to 1,460 K and its income totaled -2,870 K.
